One-on-One: TDD Talks to Leo Pharma’s Brian Hilberdink About Chronic Hand Eczema and the Delta Force Trial
Leo Pharma recently reported that delgocitinib cream, an investigational topical pan-JAK inhibitor, demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules in people with severe chronic hand eczema (CHE) in the DELTA FORCE Trial, which is the first head-to-head phase 3 trial comparing a […]